SNT 8.33% 3.9¢ syntara limited

Ann: Phase 2 Trial Reaches 50% Recruitment, page-5

  1. 443 Posts.
    lightbulb Created with Sketch. 7
    They are funded through until at least mid next year by which time they will have results of three phase 2 trials. The most important milestone this year is the interim data release for SNT 5505 in myelofibrosis - and a presentation at ASH in December. Spec buy and hold until then in my opinion.
 
watchlist Created with Sketch. Add SNT (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.